Autolus Therapeutics shares are trading higher after Goldman Sachs maintained a Neutral rating on the stock and raised its price target from $3.2 to $4.8.
Portfolio Pulse from Benzinga Newsdesk
Autolus Therapeutics' stock (AUTL) is trading higher following Goldman Sachs' decision to maintain a Neutral rating but increase the price target from $3.2 to $4.8.
December 13, 2023 | 5:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs raised the price target for Autolus Therapeutics from $3.2 to $4.8 while maintaining a Neutral rating, leading to an increase in the stock's trading price.
The increase in the price target by a reputable investment bank like Goldman Sachs typically signals a positive outlook on the stock's value, which can lead to increased investor confidence and a rise in the stock price in the short term. The Neutral rating suggests that the bank believes the stock is fairly valued at its current price, which may temper the impact slightly.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100